Appropriations Committee Passes Spending Bill with Increase in OPA Funding and Call to Action on Manufacturer Restrictions

Dept. of Health and Human Services exterior office sign and building
HRSA's Office of Pharmacy Affairs would get $13.2 million in fiscal year 2023 under a bill the House Appropriations Committee passed last week.

The U.S. Office of Pharmacy Affairs (OPA), the department within the U.S Health and Resources Administration that oversees the 340B program, would receive a $2 million increase in funding under a bill that passed through a major House committee last

Read More »

100 Congressional Democrats Urge HHS to Use Existing Power to Lower Drug Prices

soldiers marching in formation on parade ground
Congressional Democrats want HHS to use march-in rights and other existing authority to lower drug prices.

The U.S. Department of Health and Human Services should swiftly use its existing statutory authority—including forcing drug patent owners to license their products to others—to lower drug prices, 100 Democratic members of Congress urged HHS Secretary Xavier Becerra late last

Read More »

Drug Makers’ 340B Overcharging Must Be Addressed, House E&C Democrat Dingell Says During Hearing

Rep. Debbie Dingell (D-MI) headshot
Drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said during a recent hearing.

Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week.

Read More »

House Appropriators Ask Feds to Use “Any Available Measures” to Curb Pharma’s 340B Pricing Denials

U.S. House Appropriations Committee room
The U.S. House Appropriations Committee says HRSA should use "any available means" to hold drug makers accountable for curtailing "use of 340B drugs in contract pharmacies."

The U.S. House Appropriations Committee said this week it is concerned about the growing number of drug manufacturers “that curtail the use of 340B drugs in contract pharmacies.” It encouraged the U.S. Health Resources and Services Administration to use “any

Read More »

As UCB Reviews HRSA’s 340B Enforcement Letter, Grassley Presses OIG for Answers

Sen. Chuck Grassley (R-IA) speaking in a meeting with hospital employees
U.S. Sen. Chuck Grassley (R-Iowa), after meeting with 340B hospital employees in his home state, tweeted that he needs answers about drug company 340B violations and actions HHS may take.

Drug manufacturer UCB says it is reviewing Monday’s letter from the U.S. Health Resources and Services Administration telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies break federal law and must end immediately.

“At

Read More »

Sponsor Halts California Bill to Shield 340B Providers from Manufacturers and PBMs’ Actions

California State Sen. Richard Pan (D) speaking to a large assembly
California state Sen. Richard Pan (D) asked a state Assembly committee to cancel a hearing on his Senate-approved bill to prohibit drug manufacturer conditions on 340B pricing and pharmacy benefit manager discrimination against 340B covered entities.

A bill in California to prohibit drug manufacturer conditions on 340B pricing and pharmacy benefit manager discrimination against 340B covered entities died in a state Assembly committee on Tuesday.

The state Senate voted 24-9 to pass the bill, SB-939, on

Read More »

Schumer Pledges to Hold Senate Vote Soon on New Bill to Make Insulin More Affordable

Sen, Susan Collins (R-ME) speaking at a podium
U.S. Sens. Susan Collins (R-Maine), left, and Jeanne Shaheen (D-N.H.) introduced bipartisan legislation to make insulin more affordable.

A new bipartisan bill to make insulin more affordable for patients could be up for a U.S. Senate vote as early as next month. There are doubts the bill will get enough Republican support to pass, however, dooming it to

Read More »

Bill Would Give HIV/AIDS Clinics More Leeway to Use 340B Savings and Other Program Income

PrEP pill
A bill has been introduced in Congress that would get rid of a major barrier that prevents Ryan White clinics from providing PrEP to those at high risk of contracting the HIV/AIDS virus.

U.S. Sens. Rick Scott (R-Fla.) and Ben Ray Luján (D-N.M.) have introduced a bill to let Ryan White clinics use income from being in the HIV/AIDS program to provide pre-exposure prophylaxis, or PrEP, a daily medication used to prevent people

Read More »

Feds Urge Appeals Court to Overrule Lower Court in AstraZeneca’s 340B Contract Pharmacy Lawsuit

AstraZeneca wordmark building-mounted sign
The federal government wants an appeals court to rule that drug manufacturer AstraZeneca may not unilaterally dictate how many contract pharmacies a 340B covered entity may use to dispense 340B drugs.

The federal government told a federal appeals court in Philadelphia yesterday it should use “the familiar tools of statutory interpretation” to hold that drug manufacturer AstraZeneca may not unilaterally dictate how many contract pharmacies a 340B covered entity may use

Read More »

West Virginia Hardens its 340B Anti-discrimination Law to Explicitly Bar 340B Claims Modifiers

Charleston Area Medical Center exterior sign and building
West Virginia has reinforced a 2019 law to bar PBMs or other payers from requiring hospitals such as CAMC and other health care providers to include claims modifiers when billing for 340B-purchased drugs.

West Virginia has reinforced its groundbreaking 2019 law forbidding what providers say is pharmacy benefit manager discrimination against 340B covered entities.

An amendment passed in March that took effect June 10 clarifies that PBMs or other third-party payers may not require a

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live